- **Dr. Lal PathLabs is India’s largest diagnostics chain, built on a single idea that has held since 1949 - that a test result is the first and most important step in any medical decision. What began as a single pathology lab in New Delhi grew, over seven decades, into a nationwide network that now runs 200 labs and handles roughly 2.6 lakh patient samples every day. The recurring approach behind that scale is a franchise-powered hub-and-spoke model: a central reference lab does the most complex work, while thousands of neighbourhood collection centres bring the brand to the patient’s doorstep, making the cost structure more variable and the reach far wider than a company-owned chain could manage alone.** # Business segments A single diagnostic engine, organised around how patients and doctors experience it - routine and specialised testing delivered through a physical and digital network, a bundled wellness brand that now drives over a quarter of revenue, a new precision-health offering, and dedicated centres of excellence for the hardest cases. ## 1. Core diagnostic services: the hub-and-spoke engine that runs the nation’s largest test lab **A patient sample - blood, tissue, urine - travels from a neighbourhood centre to a central lab, and the company earns a fee at every step, with volume, not price, driving the business.** - **Asia’s largest reference lab as the anchor** - the National Reference Laboratory in Delhi handles the most complex work, supported by three regional reference labs in Kolkata, Bengaluru, and Mumbai; the Mumbai lab is the first private facility in West India with a BSL Level-III biocontainment unit for microbiology and virology. No other private player in India has an electron microscope; this lab has two, with the second electron microscope at the National Reference Lab in Delhi. - **Franchisees collect, the company tests** - about 45% of revenue comes through franchisee-run Patient Service Centres, and another 20-25% through Pick-up Points, so the cost base stays more variable than fixed and the network can expand without the company owning every square foot. The network stood at 7,727 Patient Service Centres and 13,935 Pick-up Points as of FY26, with over 1,100 collection centres added in that year alone. - **A test menu that stretches from routine to “first in India”** - the catalogue covers more than 4,800 tests and panels, and in FY26 the company introduced over 136 new tests, including more than 13 that no other Indian lab had offered before, such as Amyloid Typing by Laser Capture Microdissection and Mass Spectrometry (a first for South Asia) and a suite of Complement Tests. It is the world’s largest histopathology and renal biopsy testing centre by volume. - **Quality as the moat** - 40 labs hold NABL accreditation and two hold CAP accreditation; the National Reference Lab runs at a 98.0% CAP Proficiency Testing Score, and the company holds a 20-year patent for a real-time quality control monitoring system. Because roughly 70% of diagnostic errors happen before the sample even reaches the analyser, the company runs daily quality-improvement meetings with over 100 network partners and trains its phlebotomists through a dedicated programme called Project Neev. - **AI woven into the workflow, not bolted on** - the company was the first in India to deploy AI for lymph-node metastasis detection in cancer biopsies, and it now runs Agentic AI bots that handle 90% of patient calls, generating 650 extra leads a day with 30% automated conversion. A machine-learning logistics app builds routes, scans tubes, and geo-fences every sample movement, while a control tower gives real-time visibility across the entire sample-processing lifecycle. ## 2. Swasthfit: the bundled wellness brand that turned check-ups into a consumer product **A package of tests sold under a single brand name now brings in 27% of total revenue, pulling patients into the network and lifting the number of tests per visit.** - **From post-IPO launch to a quarter of the business** - Swasthfit was introduced after the 2015 listing and has grown from roughly 6-12% of revenue in FY21 to 27% in FY26, with annual growth exceeding 25% through FY25. It is overwhelmingly a retail product, not something sold to institutions, so it builds the brand directly with consumers. - **More tests per patient, not just more patients** - as Swasthfit’s share rises, the average number of tests per patient tends to rise with it, because a bundled package naturally includes more investigations than a single doctor-ordered test. In FY26, tests per patient reached 3.1, up from 3.0 the year before. - **Moving beyond the metros** - the programme plays most strongly in metro, Tier-1, and some Tier-2 cities, but the company is actively taking it into Tier-3 and Tier-4 markets, where the primary task is converting patients from the unorganised sector to a branded, trusted provider. ## 3. Sovaaka: a bet on precision health, not just disease detection **Launched in FY26, this is a concierge-led, AI-powered screening experience that tries to prevent illness rather than simply diagnose it - a new category for the company.** - **Science-led prevention, not just more tests** - Sovaaka operates under the philosophy of “Science Behind Wellness,” combining advanced diagnostics and a preventive wellness program model into a single premium health-management experience. It is positioned as an AI-powered precision health screening platform that bridges high-end diagnostics and personalised health management, moving the company beyond its traditional reactive model. ## 4. Specialty verticals - Genevolve, L-CORD, L-ACE: the centres of excellence for the hardest cases **Three dedicated units focus on genomics, reproductive diagnostics, and autoimmune disorders, building scientific credibility with clinicians and pulling in complex referrals from across the country.** - **L-CORD and L-ACE: reproductive and autoimmune depth** - L-CORD is the dedicated vertical for reproductive diagnostics, and L-ACE is the centre for autoimmune disorders, together housing Asia’s first Comprehensive Complement Testing Lab and the first Amyloid Protein Typing Facility in South Asia. These are not high-volume businesses; they are reputation anchors that make the company a “vital clinical partner” for specialists managing the most difficult cases. # Group structure and partners **The listed parent sits atop a web of domestic and international subsidiaries, most of them acquired to enter new geographies or consolidate micro-markets, with a recent clean-up that folded the Mumbai-focused Suburban Diagnostics directly into the main company.** - **Domestic subsidiaries for inorganic expansion** - PathLabs Unifiers Private Limited was incorporated specifically to hold acquired labs, and it controls three step-down entities: APRL PathLabs (80%), Centrapath Labs (70%), and Chanre Laboratory (70%). Paliwal Diagnostics (80% held) has been part of the group since 2008. - **The Suburban Diagnostics absorption** - acquired in November 2021 as the third-largest diagnostic brand in Mumbai, Suburban Diagnostics was voluntarily liquidated during FY25 and its entire business undertaking was transferred to the parent on a going-concern basis, a move aimed at cutting administrative overheads and reducing the number of group entities. - **A micro-market bolt-on in FY26** - the company acquired 100% of Shahbazkers Diagnostic Centre, a 45-year-old Mumbai lab providing pathology and basic radiology, as a way to gain a foothold in micro-markets where it had no significant presence.